Shire (SHPG) PT Set at $192.00 by Royal Bank of Canada

Royal Bank of Canada set a $192.00 price target on Shire (NASDAQ:SHPG) in a report issued on Monday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

“We don’t have a clue on the contribution of PhotonBlade in the qtr. FY18 guidance will be critical. Consensus currently is ~$52M. A number below consensus will be parsed almost immediately as to implied PhotonBlade / non- PhotonBlade growth.”,” Royal Bank of Canada’s analyst commented.

SHPG has been the topic of a number of other research reports. Cowen set a $225.00 price target on shares of Shire and gave the stock a buy rating in a report on Friday, January 5th. Zacks Investment Research raised shares of Shire from a sell rating to a hold rating in a report on Friday, October 27th. Cantor Fitzgerald reaffirmed a buy rating and issued a $222.00 price target on shares of Shire in a report on Friday, October 27th. Liberum Capital raised shares of Shire from a hold rating to a buy rating in a report on Tuesday, November 14th. Finally, ValuEngine raised shares of Shire from a hold rating to a buy rating in a report on Thursday, October 26th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of $212.50.

Shares of Shire (NASDAQ SHPG) opened at $130.42 on Monday. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55. The company has a market cap of $38,780.00, a P/E ratio of 24.56, a P/E/G ratio of 0.71 and a beta of 1.41. Shire has a 1-year low of $129.85 and a 1-year high of $192.15.

Hedge funds have recently modified their holdings of the business. SeaCrest Wealth Management LLC bought a new stake in Shire during the 4th quarter valued at $107,000. BB&T Investment Services Inc. grew its position in shares of Shire by 1,672.3% during the 3rd quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 786 shares in the last quarter. Steward Partners Investment Advisory LLC purchased a new position in shares of Shire during the 3rd quarter valued at $159,000. Benjamin F. Edwards & Company Inc. grew its position in shares of Shire by 277.4% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,253 shares of the biopharmaceutical company’s stock valued at $194,000 after purchasing an additional 921 shares in the last quarter. Finally, Regal Investment Advisors LLC purchased a new position in shares of Shire during the 4th quarter valued at $209,000. 20.31% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2018/02/08/shire-shpg-pt-set-at-192-00-by-royal-bank-of-canada.html.

Shire Company Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit